Human vaccine research and development: an overview
- PMID: 16182415
- DOI: 10.1016/j.vaccine.2005.07.077
Human vaccine research and development: an overview
Abstract
One-fifth of global mortality, especially in children under the age of five is due to infectious diseases. Vaccines are effective at combating these diseases, as shown by the success of smallpox eradication, the impressive progress towards polio eradication, the significant achievements in measles mortality reduction and many others. New safe and effective vaccines must be developed for a variety of infections of public health importance against which no effective preventive intervention measure is either available or practical. In addition, appropriate mechanisms should be put in place to ensure access for all children to the needed vaccines. To meet these challenges, a new paradigm needs to be built among all stakeholders of immunization, including countries, industry, research institutions, foundations and international agencies like the World Health Organization (WHO) and the United Nations Children Fund (UNICEF). Importantly, developing countries should be empowered to participate actively in the development and introduction of new vaccines according to their national priorities.
Similar articles
-
New vaccine introduction in the East and Southern African sub-region of the WHO African region in the context of GIVS and MDGs.Vaccine. 2012 Sep 7;30 Suppl 3:C3-8. doi: 10.1016/j.vaccine.2012.05.086. Vaccine. 2012. PMID: 22939018 Review.
-
Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.Vaccine. 2005 Aug 31;23(37):4610-8. doi: 10.1016/j.vaccine.2005.04.044. Vaccine. 2005. PMID: 15979769
-
Vaccine preventable deaths and the Global Immunization Vision and Strategy, 2006-2015.MMWR Morb Mortal Wkly Rep. 2006 May 12;55(18):511-5. MMWR Morb Mortal Wkly Rep. 2006. PMID: 16691182
-
The Children's Vaccine Initiative.Afr Health. 1997 Nov;20(1):15. Afr Health. 1997. PMID: 12348372
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
Cited by
-
Risk in vaccine research and development quantified.PLoS One. 2013;8(3):e57755. doi: 10.1371/journal.pone.0057755. Epub 2013 Mar 20. PLoS One. 2013. PMID: 23526951 Free PMC article.
-
Use of a multiplex PCR/RT-PCR approach to assess the viral causes of influenza-like illnesses in Cambodia during three consecutive dry seasons.J Med Virol. 2010 Oct;82(10):1762-72. doi: 10.1002/jmv.21891. J Med Virol. 2010. PMID: 20827775 Free PMC article.
-
Conformation-specific antibodies targeting the trimer-of-hairpins motif of the human T-cell leukemia virus type 1 transmembrane glycoprotein recognize the viral envelope but fail to neutralize viral entry.J Virol. 2007 Jun;81(11):6019-31. doi: 10.1128/JVI.02544-06. Epub 2007 Mar 21. J Virol. 2007. PMID: 17376912 Free PMC article.
-
Vaccine Production in Africa: A Feasible Business Model for Capacity Building and Sustainable New Vaccine Introduction.Front Public Health. 2019 Mar 20;7:56. doi: 10.3389/fpubh.2019.00056. eCollection 2019. Front Public Health. 2019. PMID: 30949465 Free PMC article.
-
Severe viral respiratory infections: are bugs bugging?Mucosal Immunol. 2014 Mar;7(2):227-38. doi: 10.1038/mi.2013.93. Epub 2013 Nov 13. Mucosal Immunol. 2014. PMID: 24220300 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical